2023
Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study
Roh M, Zongo I, Haro A, Huang L, Somé A, Yerbanga R, Conrad M, Wallender E, Legac J, Aweeka F, Ouédraogo J, Rosenthal P. Seasonal Malaria Chemoprevention Drug Levels and Drug Resistance Markers in Children With or Without Malaria in Burkina Faso: A Case-Control Study. The Journal Of Infectious Diseases 2023, 228: 926-935. PMID: 37221018, PMCID: PMC10547452, DOI: 10.1093/infdis/jiad172.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionDrug levelsMonths of ageOdds ratioHigh-level SP resistanceSP-AQCase-control studyConditional logistic regressionLow drug levelsPrevalence of mutationsDrug resistance markersCase-control designResistance markersIncident malariaParasitemic childrenMalaria chemopreventionAntimalarial resistanceChildren 6Health facilitiesSP resistanceChildren 3Malaria incidenceDrug resistanceMalariaLogistic regression
2022
Small-quantity lipid-based nutrient supplements, with or without added zinc, do not cause excessive fat deposition in Burkinabe children: results from a cluster-randomized community trial
Abbeddou S, Jimenez E, Hess S, Somé J, Ouédraogo J, Brown K. Small-quantity lipid-based nutrient supplements, with or without added zinc, do not cause excessive fat deposition in Burkinabe children: results from a cluster-randomized community trial. European Journal Of Nutrition 2022, 61: 4107-4120. PMID: 35829783, PMCID: PMC9596589, DOI: 10.1007/s00394-022-02936-6.Peer-Reviewed Original ResearchConceptsSmall-quantity lipid-based nutrient supplementsNon-intervention cohortLipid-based nutrient supplementsIntervention cohortIntervention groupCluster-randomized community trialFat-free mass accretionAdditional zinc supplementationFat depositionTrial registrationThe studyCluster-randomized trial designDispersible tabletsMonths of ageExcessive fat depositionMorbidity treatmentNIC childrenNutrient supplementsBurkinabe childrenUS National InstitutesObesity riskZinc supplementationClinical trialsCommunity trialFat massTrial design
2021
Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention
Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga R, Diarra M, Nikièma F, Tapily A, Sompougdou F, Issiaka D, Zoungrana C, Sanogo K, Haro A, Kaya M, Sienou A, Traore S, Mahamar A, Thera I, Diarra K, Dolo A, Kuepfer I, Snell P, Milligan P, Ockenhouse C, Ofori-Anyinam O, Tinto H, Djimde A, Ouédraogo J, Dicko A, Greenwood B. Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention. New England Journal Of Medicine 2021, 385: 1005-1017. PMID: 34432975, DOI: 10.1056/nejmoa2026330.Peer-Reviewed Original ResearchConceptsUncomplicated malariaProtective efficacyClinical malariaSevere malariaMalaria-related outcomesSeasonal malaria chemopreventionUncomplicated clinical malariaVaccine-alone groupWorld Health Organization definitionPrespecified noninferiority marginMonths of ageMalaria chemopreventionSeasonal vaccinationFirst doseHazard ratioMalaria vaccinationFebrile seizuresHospital admissionCombination groupNoninferiority marginLower incidenceAS01ChemopreventionChildren 5Organization definition
2019
Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention
Chandramohan D, Dicko A, Zongo I, Sagara I, Cairns M, Kuepfer I, Diarra M, Barry A, Tapily A, Nikiema F, Yerbanga S, Coumare S, Thera I, Traore A, Milligan P, Tinto H, Doumbo O, Ouedraogo J, Greenwood B. Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention. New England Journal Of Medicine 2019, 380: 2197-2206. PMID: 30699301, DOI: 10.1056/nejmoa1811400.Peer-Reviewed Original ResearchMeSH KeywordsAmodiaquineAnti-Bacterial AgentsAntimalarialsAzithromycinBurkina FasoChild MortalityChild, PreschoolDrug Administration ScheduleDrug CombinationsDrug Therapy, CombinationFemaleHospitalizationHumansIncidenceInfantInfant MortalityMalariaMaleMaliMass Drug AdministrationParasitemiaPyrimethamineSulfadoxineConceptsSeasonal malaria chemopreventionAddition of azithromycinMalaria transmission seasonMalaria chemopreventionHospital admissionAnnual malaria transmission seasonsUpper respiratory tract infectionNonmalarial febrile illnessesPrimary end pointRespiratory tract infectionsAntimalarial agentsLow disease burdenYears of ageMonths of ageAzithromycin groupCause mortalityPlacebo groupAdverse eventsFebrile illnessMalaria parasitemiaTract infectionsTreat analysisElective surgeryDisease burdenGastrointestinal infections
2018
Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules
Moïsi J, Yaro S, Kroman S, Gouem C, Bayane D, Ganama S, Meda B, Nacro B, Njanpop-Lafourcade B, Ouangraoua S, Ouedraogo I, Sakande S, Sawadogo F, Zida S, Ouedraogo J, Gessner B. Immunogenicity and Reactogenicity of 13-Valent Pneumococcal Conjugate Vaccine Among Infants, Toddlers, and Children in Western Burkina Faso: Results From a Clinical Trial of Alternative Immunization Schedules. Journal Of The Pediatric Infectious Diseases Society 2018, 8: 422-432. PMID: 30299491, DOI: 10.1093/jpids/piy075.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAntibodies, BacterialBurkina FasoChild, PreschoolFemaleHumansImmunization ScheduleImmunization, SecondaryImmunogenicity, VaccineImmunoglobulin GInfantMaleOpsonin ProteinsPhagocytosisPneumococcal InfectionsPneumococcal VaccinesSerogroupStreptococcus pneumoniaeVaccines, ConjugateConceptsPneumococcal conjugate vaccineMonths of ageConjugate vaccineStudy armsImmune responseDoses of PCVAge groupsDoses 2 monthsSerum immunoglobulin G concentrationBurden of morbidityStreptococcus pneumoniae infectionStrong primary immune responsesRoutine immunization programPrimary immune responseRobust memory responsesMajority of serotypesYears of ageWeeks of ageImmunoglobulin G concentrationBooster doseReactogenicity dataReactogenicity profileSatisfactory immunogenicityOpsonophagocytic activityPneumoniae infection
2017
Additional Zinc Delivered as a Tablet and SQ‐LNS May Increase Fat Free Mass Accrual in Young Burkinabe Children
Jimenez E, Abbeddou S, Coulibaly N, Some J, Ouedraogo J, Brown K, Hess S. Additional Zinc Delivered as a Tablet and SQ‐LNS May Increase Fat Free Mass Accrual in Young Burkinabe Children. The FASEB Journal 2017, 31 DOI: 10.1096/fasebj.31.1_supplement.316.2.Peer-Reviewed Original ResearchNon-intervention cohortFat-free massSQ-LNSIntervention cohortDose groupMonths of ageBody compositionBurkinabe childrenNIC groupZinc tabletsSmall-quantity lipid-based nutrient supplementsBaseline fat-free massFree massLipid-based nutrient supplementsWeight gainYoung Burkinabe childrenChildren's body compositionCollection of salivaSubgroup of childrenTwo-stage clusterNIC childrenOverall weight gainFat massIC groupSupplemental zincSmall-quantity lipid-based nutrient supplements containing different amounts of zinc along with diarrhea and malaria treatment increase iron and vitamin A status and reduce anemia prevalence, but do not affect zinc status in young Burkinabe children: a cluster-randomized trial
Abbeddou S, Yakes Jimenez E, Somé J, Ouédraogo J, Brown. K, Hess S. Small-quantity lipid-based nutrient supplements containing different amounts of zinc along with diarrhea and malaria treatment increase iron and vitamin A status and reduce anemia prevalence, but do not affect zinc status in young Burkinabe children: a cluster-randomized trial. BMC Pediatrics 2017, 17: 46. PMID: 28152989, PMCID: PMC5288861, DOI: 10.1186/s12887-016-0765-9.Peer-Reviewed Original ResearchConceptsSmall-quantity lipid-based nutrient supplementsNon-intervention cohortLipid-based nutrient supplementsRetinol-binding proteinIntervention cohortAnemia prevalenceIllness treatmentIC childrenYoung Burkinabe childrenLower retinol-binding proteinSoluble transferrin receptorLower anemia prevalenceIron deficiency prevalenceCluster-randomized trialIndicators of ironPackage of interventionsIndicator of vitaminMonths of ageDifferent treatment groupsGroup-wise differencesTwo-stage clusterNIC childrenNutrient supplementsResultsAt baselineBurkinabe children
2016
Factors Affecting the Validity of Coverage Survey Reports of Receipt of Vitamin A Supplements During Child Health Days in Southwestern Burkina Faso
Ouédraogo C, Becquey E, Wilson S, Prince L, Ouédraogo A, Rouamba N, Ouédraogo J, Vosti S, Brown K, Hess S. Factors Affecting the Validity of Coverage Survey Reports of Receipt of Vitamin A Supplements During Child Health Days in Southwestern Burkina Faso. Food And Nutrition Bulletin 2016, 37: 529-543. PMID: 27604622, DOI: 10.1177/0379572116666167.Peer-Reviewed Original ResearchConceptsOral polio vaccineOdds ratioChildren 6High-dose vitaminVitamin A supplementsCross-sectional studyLongitudinal studyMonths old childrenCaregivers of childrenChild Health DaysMonths of ageCross-sectional surveyFalse positive reportingSupplementation coverageVAS coverageFalse positive reportsA supplementsOral vaccinePolio vaccineCoverage surveyHealth daysOlder childrenVASMonthsWeeks
2015
Comparison of methods to assess adherence to small‐quantity lipid‐based nutrient supplements (SQ‐LNS) and dispersible tablets among young Burkinabé children participating in a community‐based intervention trial
Abbeddou S, Hess S, Yakes Jimenez E, Somé J, Vosti S, Guissou R, Ouédraogo J, Brown K. Comparison of methods to assess adherence to small‐quantity lipid‐based nutrient supplements (SQ‐LNS) and dispersible tablets among young Burkinabé children participating in a community‐based intervention trial. Maternal And Child Nutrition 2015, 11: 90-104. PMID: 25521188, PMCID: PMC6860357, DOI: 10.1111/mcn.12162.Peer-Reviewed Original ResearchConceptsSmall-quantity lipid-based nutrient supplementsPlasma zinc concentrationDispersible tabletsLipid-based nutrient supplementsCaregiver-reported adherenceMonths of supplementationDisappearance rateMonths of ageSubgroup of childrenWeekly adherenceIntervention trialsClinical trialsLow adherenceSupplementation trialAdherence dataHome visitsCaregiver interviewsZinc tabletsLack of changeChildren 11Zinc concentrationsStudy outcomesObservation periodAdherenceMonthsIodine status of young Burkinabe children receiving small-quantity lipid-based nutrient supplements and iodised salt: a cluster-randomised trial
Hess S, Abbeddou S, Jimenez E, Ouédraogo J, Brown K. Iodine status of young Burkinabe children receiving small-quantity lipid-based nutrient supplements and iodised salt: a cluster-randomised trial. British Journal Of Nutrition 2015, 114: 1829-1837. PMID: 26411504, DOI: 10.1017/s0007114515003554.Peer-Reviewed Original ResearchConceptsSmall-quantity lipid-based nutrient supplementsLipid-based nutrient supplementsThyroid-stimulating hormoneNon-intervention cohortMonths of ageYoung Burkinabe childrenUrinary iodineNIC childrenBurkinabe childrenIodised saltNational salt iodization programSpot urinary iodineCluster-randomised trialSalt iodization programNutrient supplementsSalt iodisation programmeIodine statusLow T4Thyroglobulin concentrationIodization programTotal thyroxineBlood spotsI statusIC childrenCohortEffect of zinc added to a daily small-quantity lipid-based nutrient supplement on diarrhoea, malaria, fever and respiratory infections in young children in rural Burkina Faso: a cluster-randomised trial
Somé J, Abbeddou S, Jimenez E, Hess S, Ouédraogo Z, Guissou R, Vosti S, Ouédraogo J, Brown K. Effect of zinc added to a daily small-quantity lipid-based nutrient supplement on diarrhoea, malaria, fever and respiratory infections in young children in rural Burkina Faso: a cluster-randomised trial. BMJ Open 2015, 5: e007828. PMID: 26362661, PMCID: PMC4567679, DOI: 10.1136/bmjopen-2015-007828.Peer-Reviewed Original ResearchConceptsRespiratory tract infectionsAcute lower respiratory tract infectionSmall-quantity lipid-based nutrient supplementsIncidence of diarrheaLower respiratory tract infectionsUpper respiratory tract infectionLipid-based nutrient supplementsSQ-LNSCluster-randomised trialPlacebo tabletsLongitudinal prevalenceIntervention groupPreventive zinc supplementationFrequency of diarrheaMonths of ageYoung childrenRural Burkina FasoMorbidity surveillanceNutrient supplementsTract infectionsRespiratory infectionsUncomplicated diarrheaZinc supplementationDiarrheaFeverSmall-Quantity Lipid-Based Nutrient Supplements, Regardless of Their Zinc Content, Increase Growth and Reduce the Prevalence of Stunting and Wasting in Young Burkinabe Children: A Cluster-Randomized Trial
Hess S, Abbeddou S, Jimenez E, Somé J, Vosti S, Ouédraogo Z, Guissou R, Ouédraogo J, Brown K. Small-Quantity Lipid-Based Nutrient Supplements, Regardless of Their Zinc Content, Increase Growth and Reduce the Prevalence of Stunting and Wasting in Young Burkinabe Children: A Cluster-Randomized Trial. PLOS ONE 2015, 10: e0122242. PMID: 25816354, PMCID: PMC4376671, DOI: 10.1371/journal.pone.0122242.Peer-Reviewed Original ResearchConceptsSmall-quantity lipid-based nutrient supplementsNon-intervention cohortPlacebo tabletsLipid-based nutrient supplementsYoung Burkinabe childrenOral rehydration saltsPrevalence of stuntingIncidence of diarrheaCluster-randomized trialPlasma zinc concentrationMonths of ageBaseline hemoglobinMorbidity surveillanceNutrient supplementsStandard careDiarrhea treatmentRehydration saltsAnemia prevalenceBurkinabe childrenIllness surveillanceAntimalarial therapyIntervention groupIllness treatmentZinc tabletsZinc levels
2014
Burkinabe infants given small quantity lipid‐based nutrient supplements and illness treatment in infancy score higher in motor, language, and personal‐social development (251.1)
Prado E, Abbeddou S, Jimenez E, Somé J, Ouédraogo Z, Vosti S, Dewey K, Hess S, Ouédraogo J, Brown K. Burkinabe infants given small quantity lipid‐based nutrient supplements and illness treatment in infancy score higher in motor, language, and personal‐social development (251.1). The FASEB Journal 2014, 28 DOI: 10.1096/fasebj.28.1_supplement.251.1.Peer-Reviewed Original ResearchSmall-quantity lipid-based nutrient supplementsLipid-based nutrient supplementsPersonal-social developmentNon-intervention communitiesYoung Burkinabe childrenTreatment of malariaMonths of ageRural Burkina FasoNutrient supplementsSQ-LNSBurkinabe childrenIllness treatmentBrain growthAdequate nutritionMacronutrient metabolismBrain developmentIC childrenMelinda Gates FoundationDevelopment of motorChildrenMalariaLowest decileTreatmentGrant funding sourcesSD
2013
Associations Between Intestinal Mucosal Function and Changes in Plasma Zinc Concentration Following Zinc Supplementation
Wessells K, Hess S, Rouamba N, Ouédraogo Z, Kellogg M, Goto R, Duggan C, Ouédraogo J, Brown K. Associations Between Intestinal Mucosal Function and Changes in Plasma Zinc Concentration Following Zinc Supplementation. Journal Of Pediatric Gastroenterology And Nutrition 2013, 57: 348-355. PMID: 23689263, PMCID: PMC4627695, DOI: 10.1097/mpg.0b013e31829b4e9e.Peer-Reviewed Original ResearchConceptsPlasma Zn concentrationsIntestinal mucosal functionMucosal functionCitrulline concentrationZn supplementationIntestinal function testsPlacebo-controlled trialMalabsorption of fatPlasma citrulline concentrationHealthy children 6Plasma zinc concentrationMonths of agePlacebo groupPlacebo supplementationUrinary lactuloseFunction testsIntestinal permeabilitySupplementation groupZinc supplementationChildren 6Vitamin AZinc absorptionDietary Zn absorptionSupplementationMineral absorption
2012
A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
Agnandji S, Lell B, Fernandes J, Abossolo B, Methogo B, Kabwende A, Adegnika A, Mordmüller B, Issifou S, Kremsner P, Sacarlal J, Aide P, Lanaspa M, Aponte J, Machevo S, Acacio S, Bulo H, Sigauque B, Macete E, Alonso P, Abdulla S, Salim N, Minja R, Mpina M, Ahmed S, Ali A, Mtoro A, Hamad A, Mutani P, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Bihoun B, Guiraud I, Kaboré B, Sombié O, Guiguemdé R, Ouédraogo J, Hamel M, Kariuki S, Oneko M, Odero C, Otieno K, Awino N, McMorrow M, Muturi-Kioi V, Laserson K, Slutsker L, Otieno W, Otieno L, Otsyula N, Gondi S, Otieno A, Owira V, Oguk E, Odongo G, Woods J, Ogutu B, Njuguna P, Chilengi R, Akoo P, Kerubo C, Maingi C, Lang T, Olotu A, Bejon P, Marsh K, Mwambingu G, Owusu-Agyei S, Asante K, Osei-Kwakye K, Boahen O, Dosoo D, Asante I, Adjei G, Kwara E, Chandramohan D, Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Mahende C, Liheluka E, Malle L, Lemnge M, Theander T, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng H, Rettig T, Bawa J, Sylverken J, Sambian D, Sarfo A, Agyekum A, Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo R, Tembo T, Tegha G, Tsidya M, Kilembe J, Chawinga C, Ballou W, Cohen J, Guerra Y, Jongert E, Lapierre D, Leach A, Lievens M, Ofori-Anyinam O, Olivier A, Vekemans J, Carter T, Kaslow D, Leboulleux D, Loucq C, Radford A, Savarese B, Schellenberg D, Sillman M, Vansadia P. A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. New England Journal Of Medicine 2012, 367: 2284-2295. PMID: 23136909, PMCID: PMC10915853, DOI: 10.1056/nejmoa1208394.Peer-Reviewed Original ResearchConceptsPhase 3 trialVaccine efficacySevere malariaWeeks of ageProtocol populationTreat populationClinical malariaCandidate malaria vaccine RTSOngoing phase 3 trialsAnti-circumsporozoite antibodiesMalaria vaccine RTSCoprimary end pointsSerious adverse eventsGeometric mean titersMonths of ageComparator vaccineAdverse eventsFirst doseFirst vaccinationMalaria episodesThird doseMean titersCox regressionMalaria vaccineAfrican infants
2011
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
Agnandji S, Lell B, Soulanoudjingar S, Fernandes J, Abossolo B, Conzelmann C, Methogo B, Doucka Y, Flamen A, Mordmüller B, Issifou S, Kremsner P, Sacarlal J, Aide P, Lanaspa M, Aponte J, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad A, Minja R, Mtoro A, Sykes A, Ahmed S, Urassa A, Ali A, Mwangoka G, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Tahita M, Kaboré W, Ouédraogo S, Sandrine Y, Guiguemdé R, Ouédraogo J, Hamel M, Kariuki S, Odero C, Oneko M, Otieno K, Awino N, Omoto J, Williamson J, Muturi-Kioi V, Laserson K, Slutsker L, Otieno W, Otieno L, Nekoye O, Gondi S, Otieno A, Ogutu B, Wasuna R, Owira V, Jones D, Onyango A, Njuguna P, Chilengi R, Akoo P, Kerubo C, Gitaka J, Maingi C, Lang T, Olotu A, Tsofa B, Bejon P, Peshu N, Marsh K, Owusu-Agyei S, Asante K, Osei-Kwakye K, Boahen O, Ayamba S, Kayan K, Owusu-Ofori R, Dosoo D, Asante I, Adjei G, Adjei G, Chandramohan D, Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Kilavo H, Mahende C, Liheluka E, Lemnge M, Theander T, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng H, Rettig T, Bawa J, Sylverken J, Sambian D, Agyekum A, Owusu L, Martinson F, Hoffman I, Mvalo T, Kamthunzi P, Nkomo R, Msika A, Jumbe A, Chome N, Nyakuipa D, Chintedza J, Ballou W, Bruls M, Cohen J, Guerra Y, Jongert E, Lapierre D, Leach A, Lievens M, Ofori-Anyinam O, Vekemans J, Carter T, Leboulleux D, Loucq C, Radford A, Savarese B, Schellenberg D, Sillman M, Vansadia P. First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. New England Journal Of Medicine 2011, 365: 1863-1875. PMID: 22007715, DOI: 10.1056/nejmoa1102287.Peer-Reviewed Original ResearchConceptsSevere malariaVaccine efficacyProtocol populationMonths of ageOlder age categoriesTreat populationClinical malariaAge categoriesCandidate malaria vaccine RTSOngoing phase 3 studiesAfrican childrenMalaria vaccine RTSPrimary end pointSerious adverse eventsPhase 3 studyPhase 3 trialDoses of vaccineWeeks of ageComparator vaccineAdverse eventsFirst doseConvulsive seizuresMalaria vaccineFirst episodeStudy groupShort-Term Zinc Supplementation with Dispersible Tablets or Zinc Sulfate Solution Yields Similar Positive Effects on Plasma Zinc Concentration of Young Children in Burkina Faso: A Randomized Controlled Trial
Wessells K, Ouédraogo Z, Rouamba N, Hess S, Ouédraogo J, Brown K. Short-Term Zinc Supplementation with Dispersible Tablets or Zinc Sulfate Solution Yields Similar Positive Effects on Plasma Zinc Concentration of Young Children in Burkina Faso: A Randomized Controlled Trial. The Journal Of Pediatrics 2011, 160: 129-135.e3. PMID: 21871635, DOI: 10.1016/j.jpeds.2011.06.051.Peer-Reviewed Original ResearchConceptsPlasma Zn concentrationsPlasma zinc concentrationPlacebo groupZinc supplementationDispersible tabletsShort-term zinc supplementationPlacebo-controlled trialMain outcome measuresYoung childrenMonths of ageControlled TrialsPlacebo solutionChildren 6Outcome measuresSD changeSupplementation resultsZinc concentrationsZinc absorptionMean plusSupplementationBurkina FasoTrialsMonthsSimilar positive effectsAge
2007
Randomized Comparison of Amodiaquine plus Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Burkina Faso
Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Séré Y, Rosenthal P, Ouédraogo J. Randomized Comparison of Amodiaquine plus Sulfadoxine-Pyrimethamine, Artemether-Lumefantrine, and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Plasmodium falciparum Malaria in Burkina Faso. Clinical Infectious Diseases 2007, 45: 1453-1461. PMID: 17990228, DOI: 10.1086/522985.Peer-Reviewed Original ResearchConceptsUncomplicated Plasmodium falciparum malariaPlasmodium falciparum malariaFalciparum malariaArtemether-lumefantrineRecurrent parasitemiaUncomplicated P. falciparum malariaCombination antimalarial therapyEarly treatment failureSerious adverse eventsP. falciparum malariaDrug-resistant parasitesYears of ageMonths of ageAntimalarial regimenDihydroartemisinin-PiperaquineLumefantrine regimenAdverse eventsCombination regimensSulfadoxine-pyrimethamineRandomized comparisonTreatment failureNew regimenRecurrent malariaAntimalarial therapyTreatment groups
1990
Vaccination against malaria: initial trial with an ant-sporozoite vaccine, (NANP)3-TT (RO 40-2361) in Africa (Bobo-Dioulasso, Burkina Faso).
Guiguemdé T, Sturchler D, Ouédraogo J, Drabo M, Etlinger H, Douchet C, Gbary A, Haller L, Kambou S, Fernex M. Vaccination against malaria: initial trial with an ant-sporozoite vaccine, (NANP)3-TT (RO 40-2361) in Africa (Bobo-Dioulasso, Burkina Faso). Bulletin De La Société De Pathologie Exotique 1990, 83: 217-27. PMID: 2119897.Peer-Reviewed Original ResearchConceptsDoses of TTAntibody titresCircumsporozoite proteinAverage antibody titresPeak IgG responseMonths of ageClinical malariaIgG responsesSystemic reactionsProtective efficacyVaccine trialsImmunological statusImmunisation vaccinesTetanus toxoidProtective effectGroup IIMalaria transmissionDay 0VaccineGroup IGroup IIIPlasmodium falciparumDay 75MalariaDay 150